Australia Breaking News

Resolute Mining (ASX:RSG) has lowered its full-year 2026 gold production target to 205,000–225,000 ounces.

Jade Gas (ASX:JGH) has launched an exploration initiative targeting deeper gas-bearing horizons beneath the shallow coal seams at its flagship TTCBM Project.

Metal Hawk (ASX:MHK) has secured firm commitments to raise $1.2 million through a private placement ahead of drilling at its 100%-owned Leinster South Project.

Pursuit Minerals (ASX:PUR) has commenced diamond drilling at its Demasía tenement in Salta Province, Argentina.

The impasse in the Black Sea following a summer escalation in Russia's war with Ukraine is compounding the economic damage from the conflict in the Middle East by threatening to drive inflation even higher. Connecting Europe and Asia, the Black Sea is a critical conduit for global crop shipments to some of the world's most populous nations. Bloomberg's Pyotr Kozlov reports.

Motio (ASX:MXO) has agreed to be acquired by IVE Group Australia, a subsidiary of IVE Group (ASX:IGL).

Dorothee Blessing, Global Investment Banking Co-Head at JPMorgan, says it's been a busy year for dealmaking. She speaks exclusively with Menaka Doshi from the sidelines of the JPMorgan India Conference.

Kingsgate Consolidated (ASX:KCN) faces a lawsuit from its political risk insurers in the Supreme Court of New South Wales.

US Treasury Secretary Scott Bessent, speaking after hours of talks with China's Vice Premier He Lifeng and other officials, said the two sides agreed to set up a dialogue on AI aimed at reaching a common understanding on goals and threats. Bessent's comments on "very successful" talks on AI, trade and investment with his Chinese counterparts came ahead of this week's summit between presidents Donald Trump and Xi Jinping.

Vulcan Energy Resources (ASX:VUL) commenced commercial-scale production of its proprietary VULSORB lithium extraction material.

Nexus Minerals (ASX:NXM) has received firm commitments for a capital placement to raise approximately $5.4 million before costs.

Neurotech International (ASX:NTI) has dosed the first patient in its pivotal Phase 3 "Beyond Harmony" clinical trial.